BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 20/05/2026 pm IST			5-day change	1st Jan Change
321.80 ^SEK	+1.51%		-0.43%	+3.54%

09:48am	Goldman Sachs cuts Bioarctic price target to SEK 339 (355), reiterates Neutral - BN	FW
20/05	BioArctic AB, Q1 2026 Earnings Call, May 20, 2026

Nordea Raises Price Target for Bioarctic to 240 Kronor (236), Reiterates Sell

Published on 02/20/2026 at 11:39 am IST

Finwire - Translated by Marketscreener - See original

BIOARCTIC AB

+1.51%

Nordea raises its price target for Bioarctic to 240 kronor (previously 236), reiterating its sell recommendation.

Latest news about BioArctic AB

09:48am	Goldman Sachs cuts Bioarctic price target to SEK 339 (355), reiterates Neutral - BN	FW
20/05	BioArctic AB, Q1 2026 Earnings Call, May 20, 2026
20/05	Bioarctic: Strong royalty growth and milestone payment lift Q1 ahead of consensus	FW
20/05	BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
20/05	Calendar Wednesday May 20	FW
15/05	Bioarctic expected to report operating profit of SEK 66 million - Modular	FW
15/05	RX Securities reiterates Buy for Bioarctic - raises fair value	FW
15/05	Bioarctic: Leqembi to generate about SEK 880 million in royalty	RE
15/05	Eisai forecasts robust growth for Leqembi – Bioarctic poised for 880 million SEK in royalties	FW
15/05	Biogen advances Alzheimer's drug to pivotal trials	FW
08/05	US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy	MT
08/05	Futures point to negative opening for Stockholm Stock Exchange (update)	FW
08/05	FDA extends review period for Leqembi Iqlik	FW
29/04	Stockholm edges lower amid earnings deluge, OMXS30 index sheds 0.5 percent	FW
29/04	Volvo Cars and AstraZeneca retreat on earnings, OMXS30 index remains flat	FW

BioArctic AB is a Swedenâ€‘based biopharmaceutical company specializing in the discovery and development of diseaseâ€‘modifying treatments for neurodegenerative disorders. The Companyâ€™s primary focus is on conditions that affect the central nervous system (CNS), including Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis (ALS), areas characterized by high unmet medical need and limited effective therapies. BioArctic AB conducts advanced research and development of innovative biological drugs, with a particular emphasis on monoclonal antibodies designed to target the underlying disease mechanisms rather than only alleviating symptoms. The Company combines inâ€‘house scientific expertise with strategic collaborations with global pharmaceutical partners to advance and commercialize its therapeutic candidates worldwide.

Employees

129

Sector

Biotechnology & Medical Research

Calendar

20/05 - Earnings release - Q1 2026

More about the company